PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $16 at Needham & Company
May 14, 2021 1:51 PM EDTNeedham & Company analyst Chad Messer lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $16.00 (from $19.00) while maintaining a Buy rating.
The analyst commenetd, "In March, PhaseBio announced enrollment in the Phase III REVERSE-IT trial was running ahead of schedule, enrolling... More
